AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450
关于我们
AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions. The company is dedicated to innovation in the rapidly expanding therapeutic botulinum toxin market. This therapeutic-only focus will allow AEON Biopharma to advance safe and effective treatment options to patients, while delivering differentiated economics to payors and physicians. The company continues to evaluate additional therapeutic indications for development based on a comprehensive product assessment process designed to identify those indications where it believes ABP-450 can attain clinical, regulatory and commercial success.
- 网站
-
https://www.aeonbiopharma.com
AEON Biopharma, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- Irvine，CA
- 类型
- 私人持股
地点
-
主要
获取路线
5 Park Plaza
Suite 1750
US，CA，Irvine，92614
AEON Biopharma, Inc.员工
-
Robert Edward Grant
Entrepreneur and Best-Selling Author of 'PHILOMATH', 'POLYMATH' and 'NEUROMINED'
-
Marc Forth
President and Chief Executive Officer at AEON Biopharma, Inc.
-
Alex Wilson
EVP, Chief Legal Officer & Corporate Secretary at AEON Biopharma, Inc.
-
Jennifer Sy
Corporate Finance & Accounting Consultant | CPA | UCLA | Big Four